Fujifilm’s facts and figures

Kenji Sukeno,
Chairman, Representative Director and Board Chairman,
FUJIFILM Holdings Corporation.

Teiichi Goto,
President and Chief Executive Officer,
FUJIFILM Holdings Corporation.

Around the world, this day and tomorrow, millions of people will experience healthcare solutions made more cost effective and efficient by our products and services.

And countless more patients will receive drugs from our laboratories that are designed to improve their outcome.

Fujifilm is entirely focused on the technologies and therapies that will make this possible.

Commitment to healthcare

FUJIFILM Holdings Corporation has 310 consolidated subsidiaries worldwide – with 73,275 employees – who all contribute to the output of this dynamic organization, working tirelessly to improve the quality of our collective lives.

With global revenues of $21 billion* overall, our Healthcare business alone generates $5.4 billion**, set to rise as populations prosper and grow, and their expectations for healthy lives increase.

* As of March 31, 2021 at an exchange rate of 106 yen to the U.S. dollar.

** Global Healthcare business revenue include medical devices, pharmaceuticals, contract development and manufacturing, regenerative medicine, cosmetics and supplements. Not all products and services are available in the United States.

Companies worldwide 310

Employees worldwide 73,275

Global revenue $21 billion*

Global healthcare revenue $5.4 billion**

Fujifilm’s legacy and history

1936

First steps in the development of X-ray.

Though often perceived as a film and photography company, Fujifilm developed from its very beginning as a medical imaging specialist.

Innovation in diagnostic imaging

Our first steps in the development of X-ray film in 1936, and later advances in imaging film and archiving film, set the course for a long line of breakthrough technologies.

The 1980s saw the digital revolution break new ground, bringing a fundamental change in the transmission and sharing of data; Fujifilm developed the world’s first digital X-ray system, bringing new speeds and efficiencies, and achieving wider availability for patients, along with reductions in operational costs.

Toward the end of the 20th century the Internet was born, along with the emergence of dynamic networks, informatics and the management and sharing of data across systems. Fujifilm introduced Synapse® to the market in 1999, combining the revolution in information technology with the networking of diagnostic imaging systems.

Entry into pharmaceutical therapies

The 21st century heralds a new era in pharmacology and we are taking major steps to become a comprehensive healthcare company, adding this integral capability to our portfolio. In 2008, Fujifilm acquired Toyama Chemical, bringing strong expertise in the research and development of drugs to fight infectious and neurological diseases.

All of these diagnostic and therapeutic technologies form a highly connected and holistic approach to healthcare, with the goal of helping patients along the entire care pathway, from the earliest diagnosis right through to the development of new regenerative treatments.

1980s

Fuji Computed Radiology (FCR), the first digital radiography system in the world, was released in 1983. FCR was developed through Fujifilm’s pioneering technology in a new field, leading to widespread digitization of radiography as well as creating the foundation for advanced 3D imaging applications and lower radiation dose.